Long-Term Follow Up of VOY-101 Non-nAMD Extension Study

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Perceive Biotherapeutics, Inc.
Study ID
NCT07660640
Status
Enrolling By Invitation

Conditions

  • Age-Related Macular Degeneration (AMD)
  • Non-Neovascular Age-Related Macular Degeneration

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • observational study — OTHER
    No intervention - observational study
  • VOY-101 — BIOLOGICAL
    One-time intravitreal injection of VOY-101.

Study Details

Long-Term Follow Up Extension for participants previously enrolled in a VOY-101 study for Advanced Non-Neovascular Age-Related Macular Degeneration

Key Dates

First listed
Jun 22, 2026
Start date
Mar 3, 2026
Status verified
Feb 2026
Primary completion
Jul 30, 2031
Completion
Aug 30, 2031

Study Design

Enrollment
88 participants (estimated)

Arms

  • Arm: Rollover from PBI-AMD-001 and PBI-AMD-002 studies for those participants who received VOY-101
    Long-term safety extension from PBI-AMD-001 and PBI-AMD-002 studies for those participants who received VOY-101

Primary Outcome Measure

Frequency of ocular and systemic VOY-101 related AEs [ Time Frame: 3 years ]

Locations (3)

FacilityCityStateZIPSite coordinators
Ophthalmic Consultants of BostonBostonMassachusetts02114-
Retina Consultants of TexasBellaireTexas77401-
University of UtahSalt Lake CityUtah84132-

Find similar trials in Boston, MA

By research site
Ophthalmic Consultants of Boston· Boston, MARetina Consultants of Texas· Bellaire, TXUniversity of Utah· Salt Lake City, UT

Related Studies